Partner Headlines - ARNA

  1. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  4. Earnings Scheduled For November 3, 2014

    Benzinga
  5. 3 Pharma Companies Fighting Obesity

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  8. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  9. Earnings Scheduled For August 1, 2014

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  12. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  15. FDA delays Orexigen drug

    IBD
  16. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  17. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  18. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  19. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  20. Earnings Scheduled For May 12, 2014

    Benzinga
  21. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  22. Benzinga's Top #PreMarket Losers

    Benzinga
  23. Earnings Scheduled For February 27, 2014

    Benzinga
  24. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  25. Top Trending Tickers On StockTwits For February 14

    Benzinga
  26. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  27. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  28. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  29. The Top Five Drug Launches Of 2013

    IBD
  30. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  31. Benzinga's Top #PreMarket Gainers

    Benzinga
  32. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  33. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  34. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  35. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  36. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  37. Benzinga's Top #PreMarket Losers

    Benzinga
  38. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  39. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  40. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  41. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  42. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  43. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  44. Benzinga's Top Pre-Market Losers

    Benzinga
  45. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  46. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  47. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  48. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  49. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  50. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  51. Stocks Hitting 52-Week Lows

    Benzinga
  52. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  53. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  54. Stocks Hitting 52-Week Lows

    Benzinga
  55. Stocks Hitting 52-Week Lows

    Benzinga
  56. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  57. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  58. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  59. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  60. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  61. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  62. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  63. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  64. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  65. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  66. Vivus fell 4.2% to 13.72

    IBD
  67. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  68. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  69. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  70. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  71. Benzinga's Top Pre-Market Gainers

    Benzinga
  72. The Best Small Cap Performers of 2012

    Benzinga
  73. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  74. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  75. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  76. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  77. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  78. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  79. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  80. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  81. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  82. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  83. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  84. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  85. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  86. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  87. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  88. Short Sellers Shy Away from Biotech Firms

    Benzinga
  89. Benzinga's Top Pre-Market Gainers

    Benzinga
  90. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  91. Health Care Sector Wrap

    FoxBusiness
  92. Short Interest in Biotech Firms on the Rise

    Benzinga
  93. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  94. Health Care Sector Wrap

    FoxBusiness
  95. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  96. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  97. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  98. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
  99. Arena Pharmaceuticals (ARNA) Falls 8.3% After Rival Weight Loss ...

    MarketIntelligenceCenter
  100. Wednesday Market Movers

    Benzinga
Trading Center